Abbott Biotechnology Ltd.

Hendricus Rjm Hoogenboom

Boris Labkovsky

Jochen G Salfeld

Tristan J Vaughan

Zehra Kaymakcalan

Michael White

Brian Timothy McGuinness

Alison Jane Wilton

Paul Sakorafas

John A Mankovich

David Schoenhaut

Deborah J Allen

Andrew J Roberts

Brian T Mcguinness

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1; and methods of using same

Growing community of inventors

Hasselt, Belgium

Hendricus Rjm Hoogenboom